EPISODE · Apr 5, 2022 · 33 MIN
Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Context and Impact of New Data
from Keeping Current CME
Did you know that noncovalent BTK inhibitors are potentially the answer to the development of resistance to covalent BTK inhibitors? Credit available for this activity expires: 4/5/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/971263?src=mkm_podcast_addon_971263
Embed this episode
NOW PLAYING
Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Context and Impact of New Data
0:00
33:30
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Keeping Current CME?
This episode is 33 minutes long.
When was this Keeping Current CME episode published?
This episode was published on April 5, 2022.
Can I download this Keeping Current CME episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!